La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Innovative Pharmaceutical Biotech Salute del bilancio

Salute finanziaria criteri di controllo 0/6

Innovative Pharmaceutical Biotech ha un patrimonio netto totale di HK$319.4M e un debito totale di HK$1.1B, che porta il suo rapporto debito/patrimonio netto a 330%. Le sue attività totali e le sue passività totali sono rispettivamente HK$1.4B e HK$1.1B.

Informazioni chiave

330.0%

Rapporto debito/patrimonio netto

HK$1.05b

Debito

Indice di copertura degli interessi	n/a
Contanti	HK$3.08m
Patrimonio netto	HK$319.43m
Totale passività	HK$1.06b
Totale attività	HK$1.38b

Aggiornamenti recenti sulla salute finanziaria

Innovative Pharmaceutical Biotech (HKG:399) Has Debt But No Earnings; Should You Worry?

Aug 12

Is Innovative Pharmaceutical Biotech (HKG:399) Using Too Much Debt?

Feb 18

Recent updates

Innovative Pharmaceutical Biotech (HKG:399) Has Debt But No Earnings; Should You Worry?

Aug 12

Robust Earnings May Not Tell The Whole Story For Innovative Pharmaceutical Biotech (HKG:399)

Jan 05

Is Innovative Pharmaceutical Biotech (HKG:399) Using Too Much Debt?

Feb 18

Innovative Pharmaceutical Biotech's(HKG:399) Share Price Is Down 80% Over The Past Five Years.

Nov 26

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( { 399 di HK$9.8M ) non coprono le sue passività a breve termine ( HK$391.6M ).

Passività a lungo termine: Le attività a breve termine di 399 ( HK$9.8M ) non coprono le sue passività a lungo termine ( HK$672.0M ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: Il rapporto debito netto/patrimonio netto ( 329.1% ) di 399 è considerato alto.

Riduzione del debito: Il rapporto debito/patrimonio netto di 399 è aumentato da 95% a 330% negli ultimi 5 anni.

Copertura del debito: Il flusso di cassa operativo di 399 è negativo, pertanto il debito non è ben coperto.

Copertura degli interessi: Dati insufficienti per determinare se i pagamenti degli interessi sul debito di 399 siano ben coperti dall'EBIT.

Innovative Pharmaceutical Biotech Salute del bilancio

Salute finanziaria criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Innovative Pharmaceutical Biotech (HKG:399) Has Debt But No Earnings; Should You Worry?

Innovative Pharmaceutical Biotech Ordinary Shares to Be Deleted from Other OTC

Is Innovative Pharmaceutical Biotech (HKG:399) Using Too Much Debt?

Recent updates

Full year 2024 earnings released: EPS: HK$0.068 (vs HK$0.17 loss in FY 2023)

Innovative Pharmaceutical Biotech Limited, Annual General Meeting, Aug 29, 2024

New minor risk - Share price stability

Full year 2024 earnings released: EPS: HK$0.068 (vs HK$0.17 loss in FY 2023)

Innovative Pharmaceutical Biotech Limited to Report Fiscal Year 2024 Results on Jun 28, 2024

Innovative Pharmaceutical Biotech Limited has filed a Follow-on Equity Offering in the amount of HKD 19.95 million.

First half 2024 earnings released: EPS: HK$0.13 (vs HK$0.079 loss in 1H 2023)

New major risk - Financial position

Innovative Pharmaceutical Biotech Limited Provides Unaudited Earnings Guidance for the Six Months Ended 30 September 2023

Innovative Pharmaceutical Biotech Limited to Report First Half, 2024 Results on Nov 29, 2023

Innovative Pharmaceutical Biotech Limited (SEHK:399) entered into a memorandum of understanding to acquire a majority interest in Niraxx Light Therapeutics, Inc.

New minor risk - Share price stability

Innovative Pharmaceutical Biotech (HKG:399) Has Debt But No Earnings; Should You Worry?

Full year 2023 earnings released: HK$0.17 loss per share (vs HK$0.031 profit in FY 2022)

Innovative Pharmaceutical Biotech Limited, Annual General Meeting, Aug 30, 2023

Innovative Pharmaceutical Biotech Limited Appoints Cheng Tak Yiu as an Executive Director

Full year 2023 earnings released: HK$0.17 loss per share (vs HK$0.031 profit in FY 2022)

Innovative Pharmaceutical Biotech Limited to Report Fiscal Year 2023 Results on Jun 29, 2023

First half 2023 earnings released: HK$0.079 loss per share (vs HK$0.085 profit in 1H 2022)

First half 2023 earnings released: HK$0.079 loss per share (vs HK$0.085 profit in 1H 2022)

Innovative Pharmaceutical Biotech Limited Provides Earnings Guidance for the Six Months Ending 30 September 2022

Innovative Pharmaceutical Biotech Limited to Report First Half, 2023 Results on Nov 29, 2022

Less than half of directors are independent

Full year 2022 earnings released: EPS: HK$0.031 (vs HK$0.14 loss in FY 2021)

Innovative Pharmaceutical Biotech Limited, Annual General Meeting, Aug 30, 2022

Innovative Pharmaceutical Biotech Ordinary Shares to Be Deleted from Other OTC

Full year 2022 earnings released

Innovative Pharmaceutical Biotech Limited to Report Fiscal Year 2023 Results on Jun 29, 2022

Less than half of directors are independent

Robust Earnings May Not Tell The Whole Story For Innovative Pharmaceutical Biotech (HKG:399)

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Innovative Pharmaceutical Biotech Limited Provides Earnings Guidance for the Six Months Ending September 30, 2021

Full year 2021 earnings released: HK$0.14 loss per share (vs HK$0.14 loss in FY 2020)

New 90-day high: HK$0.28

Is Innovative Pharmaceutical Biotech (HKG:399) Using Too Much Debt?

Innovative Pharmaceutical Biotech Limited Announces Executive Changes

New 90-day low: HK$0.24

First half 2021 earnings released: HK$0.064 loss per share

New 90-day low: HK$0.24

First half 2021 earnings released: HK$0.064 loss per share

Innovative Pharmaceutical Biotech's(HKG:399) Share Price Is Down 80% Over The Past Five Years.

Innovative Pharmaceutical Biotech Limited to Report First Half, 2021 Results on Nov 27, 2020

Innovative Pharmaceutical Biotech Limited Announces Board Changes

New 90-day high: HK$0.27

New 90-day high - HK$0.26

Mao Yumin completed the acquisition of 19.14% stake in Extrawell Pharmaceutical Holdings Limited (SEHK:858) from Innovative Pharmaceutical Biotech Limited (SEHK:399).

Full year earnings released - HK$0.14 loss per share

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Scoprire le aziende sane